Results 101 to 110 of about 755 (138)

Ticagrelor vs Prasugrel for Acute Coronary Syndrome in Routine Care.

JAMA Netw Open
Krüger N, Krefting J, Kessler T, Schmieder R, Starnecker F, Dutsch A, Graesser C, Meyer-Lindemann U, Storz T, Pugach I, Frieß C, Chen Z, Bongiovanni D, Manea I, Dreischulte T, Offenborn F, Krase P, Sager HB, Wiebe J, Kufner S, Xhepa E, Joner M, Trenkwalder T, Gueldener U, Kastrati A, Cassese S, Schunkert H, von Scheidt M, DigiMed Bayern Consortium.   +28 more
europepmc   +1 more source

Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry - Informing optimal antiplatelet strategies. [PDF]

Clin Transl Sci
Cavallari LH, Lee CR, Franchi F, Keeley EC, Rossi JS, Thomas CD, Gong Y, McDonough CW, Starostik P, Al Saeed MJ, Been L, Kulick N, Malave J, Mulrenin IR, Nguyen AB, Terrell JN, Tillotson G, Beitelshees AL, Winterstein AG, Stouffer GA, Angiolillo DJ.   +20 more
europepmc   +1 more source

Prasugrel Hydrochloride

Profiles of Drug Substances, Excipients and Related Methodology, 2015
A comprehensive profile of prasugrel HCl is reported herein with 158 references. A full description including nomenclature, formulae, elemental analysis, and appearance is included. Methods of preparation for prasugrel HCl, its intermediates, and derivatives are fully discussed.
Mahmoud M H Al Omari, Nidal A Qinna, Khaldoun A Al-Sou'Od   +2 more
exaly   +4 more sources

Prasugrel hydrochloride for the treatment of acute coronary syndrome patients

Expert Review of Cardiovascular Therapy, 2016
Dual antiplatelet therapy (DAPT) with aspirin combined with either a thienopyridine (clopidogrel or prasugrel) or acyclopentyl-triazolo-pyrimidine (ticagrelor) plays a vital role in the management of acute coronary syndrome (ACS) especially in those undergoing percutaneous coronary intervention (PCI) but even those being managed medically ...
Ashan Gunarathne, Anthony H Gershlick
exaly   +4 more sources

Relative bioavailability of prasugrel free base in comparison to prasugrel hydrochloride in the presence and in the absence of a proton pump inhibitor

Arzneimittelforschung, 2011
Prasugrel (CAS 150322-43-3), an inhibitor of platelet activation and aggregation, is indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome. If a proton pump inhibitor is co-administered with prasugrel, a pH dependent salt-to-base conversion rate of prasugrel could become clinically meaningful.
Dan, Seiler, Karlheinz, Doser, Isam, Salem   +2 more
exaly   +4 more sources

Process Improvements of Prasugrel Hydrochloride: An Adenosine Diphosphate Receptor Antagonist

Organic Process Research and Development, 2012
An improved process for the synthesis of prasugrel hydrochloride with an overall yield of 58%, 99.9% purity, and meeting all other quality requirements is described.
Sampath Aalla, Goverdhan Gilla, Dattatray Shamrao Metil, Raghupathi Reddy Anumula, Prabhaker Reddy Vummenthala, Pratap Reddy Padi   +5 more
exaly   +3 more sources

Study of the forced degradation behavior of prasugrel hydrochloride by liquid chromatography with mass spectrometry and liquid chromatography with NMR detection and prediction of the toxicity of the characterized degradation products

Journal of Separation Science, 2015
Prasugrel was subjected to forced degradation studies under conditions of hydrolysis (acid, base, and neutral), photolysis, oxidation, and thermal stress. The drug showed liability in hydrolytic as well as oxidative conditions, resulting in a total of four degradation products.
Dilip Kumar Singh, Archana Sahu, Tarun Handa   +2 more
exaly   +4 more sources

Prasugrel hydrochloride for the treatment of sickle cell disease

Expert Opinion on Investigational Drugs, 2017
Therapeutic options for sickle cell disease (SCD) are limited and, currently, only one drug (hydroxyurea) has FDA approval for the treatment of adult SCD. While this genetic disease is caused by hemoglobin polymerization, subsequent downstream events trigger platelet activation, vaso-occlusion and the disease's complex pathophysiology.
Conran, Nicola, Rees, David C
openaire   +4 more sources